Literature DB >> 16223564

Tumor development: haploinsufficiency and local network assembly.

Lubomir B Smilenov1.   

Abstract

According to the current models, tumor development is a continuous process of mutation accumulation, leading to several intermediate phenotypes and final phases of autonomy, unlimited growth and metastasis. One of the most important events in that process is the initial destabilization of cellular pathways that subsequently allow mutations to accumulate. The mechanisms involved in that stage are not clear. In principle, the estimated very low mutation frequency in human or mouse cells would suggest that accumulating the required number of mutations for tumor development should be a statistically unlikely event. However, this theory is contradicted by the high incidence of cancers. Here we discuss the role of protein haploinsufficiency as a contributor to the initial phases of tumor development, and suggest possible mechanisms that might be involved in that process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223564     DOI: 10.1016/j.canlet.2005.08.015

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Combined haploinsufficiency and genetic control of the G2/M checkpoint in irradiated cells.

Authors:  Erik F Young; Lubomir B Smilenov; Howard B Lieberman; Eric J Hall
Journal:  Radiat Res       Date:  2012-05-18       Impact factor: 2.841

3.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

Review 4.  Modeling prostate cancer in mice: limitations and opportunities.

Authors:  Patrick J Hensley; Natasha Kyprianou
Journal:  J Androl       Date:  2011-06-16

5.  RADIOSENSITIVITY TO HIGH ENERGY IRON IONS IS INFLUENCED BY HETEROZYGOSITY for ATM, RAD9 and BRCA1.

Authors:  G Zhou; L B Smilenov; H B Lieberman; T Ludwig; E J Hall
Journal:  Adv Space Res       Date:  2010-09-01       Impact factor: 2.152

6.  Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Authors:  Ajay K Yadav; Jaclyn J Renfrow; Denise M Scholtens; Hehuang Xie; George E Duran; Claudia Bredel; Hannes Vogel; James P Chandler; Arnab Chakravarti; Pierre A Robe; Sunit Das; Adrienne C Scheck; John A Kessler; Marcelo B Soares; Branimir I Sikic; Griffith R Harsh; Markus Bredel
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

7.  Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis.

Authors:  Fengtao Su; Lubomir B Smilenov; Thomas Ludwig; Libin Zhou; Jiayun Zhu; Guangming Zhou; Eric J Hall
Journal:  Radiat Oncol       Date:  2010-02-22       Impact factor: 3.481

8.  Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency.

Authors:  Alexander Pemov; Caroline Park; Karlyne M Reilly; Douglas R Stewart
Journal:  BMC Genomics       Date:  2010-03-22       Impact factor: 3.969

9.  Barrett's esophagus in the patients with familial adenomatous polyposis.

Authors:  Zoran Gatalica; Mingkui Chen; Carrie Snyder; Sumeet Mittal; Henry T Lynch
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

10.  TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

Authors:  M-C Liang; J Ma; L Chen; P Kozlowski; W Qin; D Li; J Goto; T Shimamura; D N Hayes; M Meyerson; D J Kwiatkowski; K-K Wong
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.